Zydus Lifesciences Secures FDA Approval for Pediatric PAH Treatment While Launching Respiratory Device in India
Key Insights
Zydus Lifesciences received FDA approval for generic bosentan 32 mg tablets targeting pediatric pulmonary arterial hypertension (search) in children aged three and above.
The company simultaneously launched PEPAIR (search)™, India's first affordable oscillating positive expiratory pressure device priced at ₹990 for chronic respiratory conditions.
The approved bosentan generic targets a $9.3 million annual US market segment, while over 90 lakh patients in India require airway clearance solutions.
Zydus Lifesciences has achieved a dual milestone with FDA approval for its generic pediatric pulmonary arterial hypertension (search) treatment and the launch of an innovative respiratory device in India, positioning the company for growth in both developed and domestic markets.
FDA Approval for Pediatric PAH Treatment
The United States Food and Drug Administration granted final approval for Zydus Lifesciences' 32 mg bosentan tablets for oral suspension, marking the company's entry into treating rare pediatric conditions. The approved product serves as a generic version of Tracleer® tablets, specifically targeting pulmonary arterial hypertension (search) in children aged three and above.
Industry data indicates that bosentan 32 mg tablets recorded annual sales of approximately $9.3 million in the United States as of December 2025. This positions Zydus in a competitive landscape alongside established players including Actelion Pharmaceuticals (search), Johnson & Johnson, Gilead Sciences, and Pfizer in the broader PAH market, which is projected to reach $11.2 billion globally by 2030.
The generic entry follows launches by competitors like NATCO Pharma (search) and Teva (search), intensifying competition in the U.S. generic drugs sector, valued at nearly $130 billion by 2034.
Indian Market Expansion with Respiratory Device
Concurrently, Zydus launched PEPAIR (search)™, an oscillating positive expiratory pressure (OPEP) device in India. The drug-free, handheld device targets patients with chronic lung conditions including COPD (search), asthma (search), and bronchiectasis (search). Over 90 lakh patients in India suffer from chronic respiratory conditions requiring airway clearance solutions.
Zydus positions PEPAIR (search)™ as India's first affordable OPEP device, priced at ₹990 per unit, addressing a critical gap in accessible respiratory care devices. This pricing strategy contrasts sharply with potentially higher-priced alternatives while offering a drug-free therapeutic option.
Regulatory Resolution and Financial Performance
The company achieved a significant milestone by resolving a USFDA warning letter from August 2024 with a closeout letter issued in January 2026. The original warning concerned current Good Manufacturing Practice (CGMP) violations at its Jarod facility in Gujarat, including failures in investigating contamination, inadequate procedures for aseptic processing, and equipment maintenance.
Recent financial performance shows positive momentum, with Q3 FY26 results demonstrating a 7.7% rise in net profit to Rs 1,102.64 crore and a 32.3% increase in revenue to Rs 6,780.40 crore year-on-year.
Market Position and Valuation
Zydus Lifesciences holds a market capitalization of approximately ₹91,618 crore as of February 18, 2026. The company's trailing twelve months' P/E ratio stands around 18.12 to 18.56, notably below the median P/E ratio of its peers at 30.82, suggesting a potential valuation discount.
The company operates within India's pharmaceutical sector, projected to reach $120 billion to $130 billion by 2030. India ranks third globally in pharmaceutical production volume, providing context for Zydus's strategic positioning.
Future Pipeline and Analyst Outlook
Analysts maintain a "Hold" consensus rating on Zydus Lifesciences, with an average target price of ₹999.13 INR, suggesting a modest upside potential of around 10.55%. The company signals optimism regarding its pipeline, with indications of potentially being the first to file a Biologics Licence Application (BLA) in the US for a biosimilar pembrolizumab, following an agreement for Formycon (search)'s FYB206.
Despite the positive developments, challenges remain in the competitive generic market characterized by intense price erosion, and the success of PEPAIR (search)™ depends on widespread physician endorsement and patient education in India's complex healthcare landscape.